Cocrystal Pharma (COCP) Projected to Post Quarterly Earnings on Thursday

Cocrystal Pharma (NASDAQ:COCP) is projected to issue its results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.17) per share and revenue of $0.2250 million for the quarter.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The company had revenue of $0.23 million for the quarter, compared to analysts’ expectations of $0.23 million. On average, analysts expect Cocrystal Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cocrystal Pharma Stock Performance

NASDAQ:COCP opened at $1.02 on Thursday. The company has a market cap of $14.07 million, a price-to-earnings ratio of -1.40 and a beta of 1.43. The stock’s fifty day moving average price is $0.99 and its two-hundred day moving average price is $1.10. Cocrystal Pharma has a 52-week low of $0.76 and a 52-week high of $2.67.

Institutional Trading of Cocrystal Pharma

A hedge fund recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned about 0.24% of Cocrystal Pharma as of its most recent filing with the SEC. 6.72% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.